

Novel therapies for the underserved.

Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Through the acquisition and licensing of technology rights and IP from leading universities and researchers, Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company's lead program, SPC-15, is a nose-to-brain intranasal formulation targeting PTSD and stress-induced anxiety disorders. A pre-investigational New Drug Application (pre-IND) for SPC-15 was submitted to the FDA in June 2024. The next drug in development is SP-26, a time release ketamine-loaded implant for fibromyalgia and chronic pain relief. Two preclinical programs are underway for neurological diseases: SPC-14, an intranasal compound for the treatment of Alzheimer's disease (AD), and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Columbia University has granted Silo exclusive worldwide rights to further develop, manufacture, and commercialize SPC-15 and SPC-14. Silo intends to utilize the FDA's streamlined 505(b)(2) pathway for SPC-15 and SP-26, which would shorten clinical timelines and reduce drug development costs.

Investment Highlights



Clear timeline to first-in-human clinical trials for lead asset SPC-15 pending FDA guidance on pre-IND. GLP study underway.



Exclusive global licenses granted by Columbia University to further develop, manufacture, and commercialize SPC-15 and SPC-14 worldwide.



Streamlined 505(b)(2) regulatory pathway for drug approval planned for top two priority drug candidates.



Diversified pipeline of novel IP-protected technologies and assets showing promise in underserved rare disease, neurological, and mental health indications.



Disruptive market potential in central nervous system therapeutics industry; projected CAGR of 8% for CNS drugs during the period 2022 (~\$110.4 B) to 2032 (~\$238.8 B)¹.



Assets well-protected by strong IP, with 10 issued and/or provisional patents.



Ample capital resources to support upcoming catalysts, prudent use of capital for drug development, and zero debt.



Leadership with expertise in drug development and licensing, asset acquisition, biotech management, capital markets, and finance.

¹ Global Market Insights, Central Nervous System Therapeutics Market Size, June 2023

Development Timeline

Drug and Category	Indication	Optimization/ Proof of Concept	Preclinical	Phase I	Phase II	Phase III	Catalysts
SPC-15 <i>Mental Health</i>	PTSD						Final pre-clinical studies in 2024
SP-26 <i>Chronic Pain</i>	Fibromyalgia						2024 data
SPC-14 <i>Neurology</i>	Alzheimer's Disease (AD)						2024 data
SPU-16 Peptide <i>Neurology</i>	Multiple Sclerosis (MS)						2024 data

High Value Collaborations and Assets

Four novel drug candidates target three health areas: mental health, chronic pain, and neurology.



SPC-15 | Stress-Induced Anxiety Disorder, PTSD

- Nose-to-brain intranasal prophylactic treatment utilizing a novel serotonin 4 (5-HT₄) receptor agonist
- Exclusive license from Columbia University to develop, manufacture, and commercialize SPC-15 worldwide
- PTSD affects an estimated 3.9%² of the world's population

SP-26 | Fibromyalgia and Chronic Pain

- Innovative time-release ketamine-loaded implant for fibromyalgia
- Self-administered non-opioid chronic pain solution
- Potential to be first at-home ketamine treatment for chronic pain management



SPC-14 | Alzheimer's Disease

- Targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT₄ to treat cognitive and neuropsychiatric symptoms
- Global Alzheimer's disease therapeutics market size forecasted to exceed \$30.8 billion by 2033, with CAGR of 18.8% from 2024 to 2033³



SPU-16 | Multiple Sclerosis

- Central nervous system homing peptide; designed to cross through blood-brain barrier, then home to specific damaged tissue
- Can be used for investigation and treatment of MS and other neuroinflammatory pathology

² World Health Organization, May 2024

³ Market.us., Global Alzheimer's Disease Therapeutics Market report, January 2024

Recent Announcements

August 14, 2024 — Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

August 7, 2024 — Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

July 22, 2024 — Silo Pharma Announces Closing of \$2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

July 18, 2024 — Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

July 16, 2024 — Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

July 8, 2024 — Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety

June 26, 2024 — Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

June 7, 2024 — Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

June 4, 2024 — Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Leadership

Eric Weisblum, Founder and CEO

20 years of investing, building, and managing businesses, including in-licensing and developing therapeutic assets. Formerly President of Sableridge Capital and board member of Nasdaq-listed Aikido Pharma.

Daniel Ryweck CPA, CFO

Mill City Ventures III Ltd, Sun BioPharma, Inc., Dala Petroleum Corp.

James Kuo, M.D., MBA, Vice President of R&D

Athena Bioventures, ImmunoPrecise Antibodies, Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, Discovery Laboratories, HealthCare Ventures

Charles B. Nemeroff, M.D., Ph.D., Scientific Advisor

University of Texas, University of Texas at Austin's Dell Medical School

Market Snapshot

Share Price

\$1.40 (8/21/24)

52-Wk. Range

\$0.84 - \$4.50

Avg. Vol.

5.2M

Shares O/S

4.5M

Market Cap

\$6.2M

Price and volume quotes from Yahoo! Finance

Analyst Coverage

Laidlaw & Company.

Yale Jen

Silo Pharma, Inc. | 677 N. Washington Blvd., Sarasota, FL 34236
Investor Relations Contact: 800-705-0120 | investors@silopharma.com

Forward-Looking Statements: This fact sheet contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential" and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. ("Silo" or "the Company") to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this fact sheet, whether as a result of new information, future events or otherwise, after the date of this document or to reflect the occurrence of unanticipated events except as required by law.